Group-Based Contingency Management for Substance Abuse Treatment - 1

This study is currently recruiting participants.

Verified by National Institute on Drug Abuse (NIDA), May 2008

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Connecticut Health Center
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00249717

Purpose

The purpose of this study is to evaluate the efficacy of prize-based contingency management (CM) when administered exclusively in groups. Substance dependent patients (N=360) at community-based treatment programs are randomly assigned to one of two conditions: (a) standard, non-CM treatment or (b) standard treatment plus prize CM delivered in groups. In the CM condition, patients earn the opportunity to win prizes ranging from $1 to $100 in value for attending groups and submitting drug-free biological specimens. Substance use and psychosocial problems are measured at intake, month 1, month 3 (post treatment), and at 6-, 9-, and 12-month follow-up evaluations. We also assess patient characteristics that may be associated with improved outcomes within and across conditions.

Condition	Intervention
Substance Abuse	Behavioral: Contingency management

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Official Title:	Group-Based Contingency Management for Substance Abuse Treatment

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use [ Time Frame: baseline and at each follow-up ] [ Designated as safety issue: No ]
Retention [ Time Frame: at each follow-up ] [ Designated as safety issue: No ]

Estimated Enrollment:	360
Study Start Date:	May 2005
Estimated Study Completion Date:	September 2009
Estimated Primary Completion Date:	September 2009 (Final data collection date for primary outcome measure)

Intervention Details:

Receive rewards valued between $1-$100 for abstinence and attendance

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

age > 18 years
current DSM-IV diagnosis of cocaine, opioid or alcohol abuse or dependence
willing to provide breath and urine samples for 12 weeks
English speaking
willing to sign informed consent

Exclusion criteria:

serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk)
dementia (<23 on the Mini Mental State Exam; Folstein et al. 1975)
in recovery from pathological gambling

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00249717

Contacts

Contact: Ellen M Ciesielski, B.A.

(860)679-4556

ciesielski@psychiatry.uchc.edu

Locations

United States, Connecticut
University of Connecticut Health Center	Recruiting
Farmington, Connecticut, United States, 06030
Contact: Nancy Petry, Ph.D. 860-679-2593 petry@psychiatry.uchc.edu

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Connecticut Health Center

Investigators

Principal Investigator:

Nancy Petry, Ph.D.

University of Connecticut

More Information

Responsible Party:	UConn Health Center ( Nancy Petry, Ph.D. )
Study ID Numbers:	NIDA-18883-1, R01-18883-1
Study First Received:	November 3, 2005
Last Updated:	May 23, 2008
ClinicalTrials.gov Identifier:	NCT00249717
Health Authority:	United States: Federal Government; United States: Institutional Review Board

Keywords provided by National Institute on Drug Abuse (NIDA):

Contingency management
Substance abuse treatment

Study placed in the following topic categories:

Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin

ClinicalTrials.gov processed this record on January 14, 2009